{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:27:10Z","timestamp":1761128830270},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T00:00:00Z","timestamp":1276732800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00431-010-1238-z","type":"journal-article","created":{"date-parts":[[2010,6,16]],"date-time":"2010-06-16T05:51:48Z","timestamp":1276667508000},"page":"157-167","source":"Crossref","is-referenced-by-count":35,"title":["Biologics in children\u2019s autoimmune disorders: efficacy and safety"],"prefix":"10.1007","volume":"170","author":[{"given":"Luciana","family":"Breda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Del Torto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Chiarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,17]]},"reference":[{"issue":"2\u20133","key":"1238_CR1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","volume":"38","author":"NE Aikawa","year":"2010","unstructured":"Aikawa NE, De Carvalho JF, Silva CA et al (2010) Immunogenicity of anti-TNF\u03b1 agents in autoimmune diseases. Clinic Rev Allerg Immunol 38(2\u20133):82\u201389","journal-title":"Clinic Rev Allerg Immunol"},{"issue":"3","key":"1238_CR2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.1780330302","volume":"33","author":"WP Arend","year":"1990","unstructured":"Arend WP, Dayer JM (1990) Cytokines and cytokine receptors or antagonists in rheumatoid arthritis. Arthritis Rheum 33(3):305\u2013312","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1238_CR3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11926-000-0071-1","volume":"2","author":"T Arkachaisri","year":"2000","unstructured":"Arkachaisri T, Lehman TJ (2000) Use of biologics in the treatment of childhood rheumatic diseases. Curr Rheumatol Rep 2(4):330\u2013336","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"1238_CR4","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","volume":"107","author":"CM Bennett","year":"2006","unstructured":"Bennett CM, Rogers ZR, Kinnamon DD et al (2006) Prospective phase I\/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 107(7):2639\u20132642","journal-title":"Blood"},{"issue":"3","key":"1238_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.immuni.2006.03.001","volume":"24","author":"JA Bluestone","year":"2006","unstructured":"Bluestone JA, St Clair EW, Turka LA (2006) CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24(3):223\u2013238","journal-title":"Immunity"},{"key":"1238_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1546-0096-7-3","volume":"7","author":"RJ Brogan","year":"2009","unstructured":"Brogan RJ, Eleftheriou D, Gnanapragasam J et al (2009) Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report. Pediatric Rheumatol 7:3","journal-title":"Pediatric Rheumatol"},{"issue":"12","key":"1238_CR7","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","volume":"63","author":"A Calin","year":"2004","unstructured":"Calin A, Dijkmans BA, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594\u20131600","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1238_CR8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1529-8019.2008.01213.x","volume":"22","author":"L Castelo-Soccio","year":"2009","unstructured":"Castelo-Soccio L, Van Voorhees AS (2009) Long-term efficacy of biologics in dermatology. Dermatol Ther 22(1):22\u201333","journal-title":"Dermatol Ther"},{"issue":"4","key":"1238_CR9","first-page":"733","volume":"2","author":"LD Church","year":"2008","unstructured":"Church LD, Savic S, McDermott MF (2008) Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap). Biologics 2(4):733\u2013742","journal-title":"Biologics"},{"issue":"9","key":"1238_CR10","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW et al (2006) REFLEX Trial Group. Rituximab for rheumatoid arthritis to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793\u20132806","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1238_CR11","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/ibd.20045","volume":"13","author":"S Cucchiara","year":"2007","unstructured":"Cucchiara S, Morley-Fletcher A (2007) \u201cNew drugs: kids come first\u201d: children should be included in trials of new biological treatments. Inflamm Bowel Dis 13(9):1165\u20131169","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"1238_CR12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/14622416.9.8.1011","volume":"9","author":"MI Danila","year":"2008","unstructured":"Danila MI, Hughes LB, Bridges SL (2008) Pharmacogenetics of etanercept in rheumatoid arthritis. Pharmacogenomics 9(8):1011\u20131015","journal-title":"Pharmacogenomics"},{"issue":"11","key":"1238_CR13","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J et al (2003) Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230\u20133236","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1238_CR14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/BOR.0b013e32832f1445","volume":"21","author":"F Benedetti De","year":"2009","unstructured":"De Benedetti F (2009) Targeting interleukin-6 in pediatric rheumatic diseases. Curr Opin Rheumatol 21(5):533\u2013537","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"1238_CR15","first-page":"203","volume":"25","author":"F Benedetti De","year":"1998","unstructured":"De Benedetti F, Martini A (1998) Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 25(2):203\u2013207","journal-title":"J Rheumatol"},{"issue":"1","key":"1238_CR16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00005176-200407000-00010","volume":"39","author":"L Ridder de","year":"2004","unstructured":"de Ridder L, Escher JC, Bouquet J et al (2004) Infliximab therapy in 30 patients, with refractory pediatric Crohn disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr 39(1):46\u201352","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"1238_CR17","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/eji.1830260510","volume":"26","author":"AD Dick","year":"1996","unstructured":"Dick AD, McMenamin PG, Korner H et al (1996) Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 26(5):1018\u20131035","journal-title":"Eur J Immunol"},{"issue":"8","key":"1238_CR18","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"WG Dixon","year":"2006","unstructured":"Dixon WG, Watson K, Lunt M et al (2006) British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics register. Arthritis Rheum 54(8):2368\u20132376","journal-title":"Arthritis Rheum"},{"issue":"25","key":"1238_CR19","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572\u20132581","journal-title":"N Engl J Med"},{"issue":"5","key":"1238_CR20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: result of a phase IIB randomized, double-blind, placebo-controlled, dose ranging trial. Arthritis Rheum 54(5):1390\u20131400","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1238_CR21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","volume":"121","author":"CS Foster","year":"2003","unstructured":"Foster CS, Tufail F, Waheed NK et al (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121(4):437\u2013440","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"1238_CR22","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1002\/art.20497","volume":"50","author":"J Frenkel","year":"2004","unstructured":"Frenkel J, Wulffraat NM, Kuis W (2004) Anakinra in mutation-negative NOMID\/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. Arthritis Rheum 50(11):3738\u20133739","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1238_CR23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10067-007-0654-6","volume":"27","author":"G Gartlehner","year":"2008","unstructured":"Gartlehner G, Hansen RA, Jonas BL et al (2008) Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol 27(1):67\u201376","journal-title":"Clin Rheumatol"},{"issue":"5","key":"1238_CR24","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/art.23475","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Pelagatti MA, Meini A et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis receptor-associated periodic syndrome. Arthritis Rheum 58(5):1516\u20131520","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1238_CR25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Piccini A, Lasigli\u00e8 D et al (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58(5):1505\u20131515","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1238_CR26","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis to tumor necrosis factor alpha inhibition. N Engl J Med 353(11):1114\u20131123","journal-title":"N Engl J Med"},{"issue":"3","key":"1238_CR27","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/art.20793","volume":"52","author":"V Gerloni","year":"2005","unstructured":"Gerloni V, Pontikaki I, Gattinara M et al (2005) Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor-\u03b1 monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 52(3):548\u2013553","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1238_CR28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","volume":"355","author":"R Goldbach-Mansky","year":"2006","unstructured":"Goldbach-Mansky R, Dailey NJ, Canna SW et al (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1\u03b2 inhibition. N Engl J Med 355(6):581\u2013592","journal-title":"N Engl J Med"},{"issue":"5","key":"1238_CR29","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/rheumatology\/keh547","volume":"44","author":"B Granel","year":"2005","unstructured":"Granel B, Serratrice J, Disdier P et al (2005) Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford) 44(5):689\u2013690","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1238_CR30","first-page":"205","volume":"65","author":"KA Haines","year":"2007","unstructured":"Haines KA (2007) Juvenile idiopathic arthritis: therapies in the 21st century. Bull NYU Hosp Jt Dis 65(3):205\u2013211","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"13","key":"1238_CR31","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1001\/jama.294.13.1671","volume":"294","author":"PJ Hashkes","year":"2005","unstructured":"Hashkes PJ, Laxer RM (2005) Medical treatment of juvenile idiopathic arthritis. JAMA 294(13):1671\u20131684","journal-title":"JAMA"},{"issue":"6","key":"1238_CR32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11926-006-0041-3","volume":"8","author":"PJ Hashkes","year":"2006","unstructured":"Hashkes PJ, Laxer RM (2006) Update on the medical treatment of juvenile idiopathic arthritis. Curr Rheumatol Rep 8(6):450\u2013458","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"1238_CR33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/ar2619","volume":"11","author":"K Hayward","year":"2009","unstructured":"Hayward K, Wallance CA (2009) Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res 11(1):216\u2013227","journal-title":"Arthritis Res"},{"key":"1238_CR34","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"HM Hoffman","year":"2008","unstructured":"Hoffman HM, Throne ML, Amar NJ et al (2008) Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58:2443\u20132452","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1238_CR35","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/rheumatology\/kep122","volume":"48","author":"G Horneff","year":"2009","unstructured":"Horneff G, Ebert A, Fitter S et al (2009) Safety and efficacy of once etanercept 0.8\u00a0mg\/kg in a multicentre 12\u00a0week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford) 48(8):916\u2013919","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1238_CR36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1542\/peds.109.1.109","volume":"109","author":"NT Ilowite","year":"2002","unstructured":"Ilowite NT (2002) Current treatment of juvenile rheumatoid arthritis. Pediatrics 109(1):109\u2013115","journal-title":"Pediatrics"},{"issue":"5","key":"1238_CR37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/BOR.0b013e3283060778","volume":"20","author":"NT Ilowite","year":"2008","unstructured":"Ilowite NT (2008) Update on biologics in juvenile idiopathic arthritis. Curr Opin Rheumatol 20(5):613\u2013618","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"1238_CR38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","volume":"28","author":"N Ilowite","year":"2009","unstructured":"Ilowite N, Porras O, Reiff A et al (2009) Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 28(2):129\u2013137","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1238_CR39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/ar2594","volume":"11","author":"JD Isaacs","year":"2009","unstructured":"Isaacs JD (2009) Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther 11(3):225","journal-title":"Arthritis Res Ther"},{"key":"1238_CR40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/321522a0","volume":"321","author":"PT Jones","year":"1986","unstructured":"Jones PT, Dear PH, Foote J et al (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522\u2013525","journal-title":"Nature"},{"issue":"7","key":"1238_CR41","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"RB Jones","year":"2009","unstructured":"Jones RB, Ferraro AJ, Chaudhry AN et al (2009) A multicenter survey of rituximab therapy for refractory antinuetrophil cytoplasmatic antibody-associated vasculitis. Arthritis Rheum 60(7):2156\u20132168","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1238_CR42","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10067-009-1162-7","volume":"28","author":"MM Katsicas","year":"2009","unstructured":"Katsicas MM, Russo RA (2009) Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and\/or infliximab. Clin Rheumatol 28(8):985\u2013988","journal-title":"Clin Rheumatol"},{"key":"1238_CR43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3899\/jrheum.090128","volume":"82","author":"M Khraishi","year":"2009","unstructured":"Khraishi M (2009) Comparative overview of safety of the biologics in rheumatoid arthritis. J Rheumatol Suppl 82:25\u201332","journal-title":"J Rheumatol Suppl"},{"issue":"12","key":"1238_CR44","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144(12):865\u2013876","journal-title":"Ann Intern Med"},{"key":"1238_CR45","first-page":"865","volume":"2","author":"JB Kuemmerle-Deschner","year":"2008","unstructured":"Kuemmerle-Deschner JB, Benseler SM (2008) Abatacept in difficult to treat juvenile idiopathic arthritis. Biologics 2:865\u2013874","journal-title":"Biologics"},{"issue":"4","key":"1238_CR46","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF01451007","volume":"17","author":"N Kutukculer","year":"1998","unstructured":"Kutukculer N, Caglayan S, Aydogdu F (1998) Study of pro-inflammatory (TNF-alpha, IL-1 alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol 17(4):288\u2013292","journal-title":"Clin Rheumatol"},{"issue":"23","key":"1238_CR47","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al (2009) Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360(23):2416\u20132425","journal-title":"N Engl J Med"},{"issue":"10","key":"1238_CR48","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","volume":"61","author":"MJ Leandro","year":"2002","unstructured":"Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61(10):883\u2013888","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1238_CR49","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerr\u00e9","year":"2008","unstructured":"Lequerr\u00e9 T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67(3):302\u2013308","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1238_CR50","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.20953","volume":"52","author":"DJ Lovell","year":"2005","unstructured":"Lovell DJ, Bowyer SL, Solinger AM (2005) Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 52(4):1283\u20131286","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1238_CR51","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342(11):763\u2013769","journal-title":"N Engl J Med"},{"issue":"5","key":"1238_CR52","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","volume":"58","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Reiff A, Ilowite NT et al (2008) The Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58(5):1496\u20131504","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1238_CR53","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","volume":"54","author":"DJ Lovell","year":"2006","unstructured":"Lovell DJ, Reiff A, Jones OY (2006) Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 54(6):1987\u20131994","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1238_CR54","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S et al (2008) Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810\u2013820","journal-title":"N Engl J Med"},{"issue":"suppl","key":"1238_CR55","first-page":"s303","volume":"54","author":"DJ Lovell","year":"2006","unstructured":"Lovell DJ, Ruperto N, Jung L (2006) Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results. Arthritis Rheum 54(suppl):s303","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1238_CR56","first-page":"2359","volume":"21","author":"KL Madson","year":"1994","unstructured":"Madson KL, Moore TL, Lawrence JM et al (1994) Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J Rheumatol 21(12):2359\u20132363","journal-title":"J Rheumatol"},{"issue":"9","key":"1238_CR57","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini RN, Taylor PC, Szechinski J (2006) CHARISMA Study Group. Double-blind randomized controlled clinical trial of interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54(9):2817\u20132829","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1238_CR58","first-page":"598","volume":"13","author":"A Martini","year":"1986","unstructured":"Martini A, Ravelli A, Notarangelo LD et al (1986) Enhanced interleukin 1 and depressed interleukin 2 production in juvenile arthritis. J Rheumatol 13(3):598\u2013603","journal-title":"J Rheumatol"},{"issue":"4","key":"1238_CR59","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1517\/14656566.7.4.387","volume":"7","author":"G Martini","year":"2006","unstructured":"Martini G, Zulian F (2006) Juvenile idiopathic arthritis: current and future treatment options. Expert Opin Pharmacother 7(4):387\u2013399","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"1238_CR60","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/dc09-0054","volume":"32","author":"L Mastrandrea","year":"2009","unstructured":"Mastrandrea L, Yu J, Behrens T et al (2009) Etanercept treatment in children with new-onset type 1 diabetes. Diabetes Care 32(7):1244\u20131249","journal-title":"Diabetes Care"},{"issue":"1","key":"1238_CR61","first-page":"15","volume":"32","author":"LJ McCann","year":"2007","unstructured":"McCann LJ, Woo P (2007) Biologic therapies in juvenile idiopathic arthritis: why and for whom? Acta Reumatol Port 32(1):15\u201326","journal-title":"Acta Reumatol Port"},{"issue":"7","key":"1238_CR62","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264\u20132272","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1238_CR63","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/BOR.0b013e3283295fec","volume":"21","author":"T Mima","year":"2009","unstructured":"Mima T, Nishimoto N (2009) Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 21(3):224\u2013230","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"1238_CR64","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.25057","volume":"62","author":"B Neven","year":"2010","unstructured":"Neven B, Marvillet I, Terrada C et al (2010) Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 62(1):258\u2013267","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1238_CR65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1542\/peds.2006-2015","volume":"119","author":"M Nevyiel","year":"2007","unstructured":"Nevyiel M, Pontillo A, Calligaris L et al (2007) Diagnostics and therapeutic insights in a severe case of mevalonate kinase deficiency. Pediatrics 119(2):523\u2013527","journal-title":"Pediatrics"},{"issue":"6","key":"1238_CR66","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","volume":"50","author":"N Nishimoto","year":"2004","unstructured":"Nishimoto N, Yoshizaki K, Miyasaka N et al (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50(6):1761\u20131769","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1238_CR67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1525-1470.2007.00343.x","volume":"24","author":"SM O'Connell","year":"2007","unstructured":"O'Connell SM, O'Regan GM, Bolger T et al (2007) Response to IL-1 receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 24(1):85\u201389","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"1238_CR68","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.4049\/jimmunol.168.7.3394","volume":"168","author":"ML Olleros","year":"2002","unstructured":"Olleros ML, Guler R, Corazza N et al (2002) Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-\u03b1. J Immunol 168(7):3394\u20133401","journal-title":"J Immunol"},{"key":"1238_CR69","unstructured":"Orencia product monograph (2006) Bristol Meyer Squibb Canada, Montreal. http:\/\/www.bmscanada.ca\/upload\/File\/pdf\/products\/ORENCIA_E_PM_17%20February%202010_APP_CLN.pdf"},{"key":"1238_CR70","first-page":"127","volume":"3","author":"CE Pain","year":"2009","unstructured":"Pain CE, McCann LJ (2009) Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics 3:127\u2013139","journal-title":"Biologics"},{"issue":"9","key":"1238_CR71","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","volume":"201","author":"V Pascual","year":"2005","unstructured":"Pascual V, Allantaz F, Arce E et al (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479\u20131486","journal-title":"J Exp Med"},{"key":"1238_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbspin.2006.07.001","volume":"74","author":"P Quartier","year":"2007","unstructured":"Quartier P (2007) When should we use TNF antagonist in children with rheumatic disease? Join Bone Spine 74:1\u20133","journal-title":"Join Bone Spine"},{"issue":"4","key":"1238_CR73","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pbc.21264","volume":"50","author":"A Rao","year":"2008","unstructured":"Rao A, Kelly M, Musselman M et al (2008) Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 50(4):822\u2013825","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"1238_CR74","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","volume":"44","author":"A Reiff","year":"2001","unstructured":"Reiff A, Takei S, Sadeghi S et al (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44(6):1411\u20131415","journal-title":"Arthritis Rheum"},{"key":"1238_CR75","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jbspin.2008.04.001","volume":"75","author":"R Roldan","year":"2008","unstructured":"Roldan R, Ruiz AM, Miranda MD et al (2008) Anakinra: new therapeutic approach in children with familial Mediterranean fever resistant to colchicine. Joint Bone Spine 75:504\u2013505","journal-title":"Joint Bone Spine"},{"issue":"suppl1","key":"1238_CR76","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2666","volume":"11","author":"A Rubbert-Roth","year":"2009","unstructured":"Rubbert-Roth A, Finckh A (2009) Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 11(suppl1):S1","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"1238_CR77","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R et al (2007) Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56(9):3096\u20133106","journal-title":"Arthritis Rheum"},{"key":"1238_CR78","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","volume":"69","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Cuttica R et al (2010) Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 69:718\u2013722","journal-title":"Ann Rheum Dis"},{"issue":"9636","key":"1238_CR79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P et al (2008) Paediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383\u2013391","journal-title":"Lancet"},{"issue":"23","key":"1238_CR80","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23):2462\u20132476","journal-title":"N Engl J Med"},{"issue":"6","key":"1238_CR81","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0161-6420(01)00576-0","volume":"108","author":"CM Samson","year":"2001","unstructured":"Samson CM, Waheed N, Baltatzis S et al (2001) Methotrexate therapy for chronic noninfectious uveitis. Ophthalmology 108(6):370\u2013374","journal-title":"Ophthalmology"},{"issue":"8","key":"1238_CR82","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","volume":"44","author":"H Schmeling","year":"2005","unstructured":"Schmeling H, Horneff G (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 44(8):1008\u20131011","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1238_CR83","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4103\/0972-5229.45079","volume":"12","author":"R Sharma","year":"2008","unstructured":"Sharma R, Lal Sharma C, Mahajan A (2008) Biological agents targeting beyond TNF-alpha. Indian J Crit Care Med 12(4):181\u2013189","journal-title":"Indian J Crit Care Med"},{"issue":"3","key":"1238_CR84","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1601-0825.2008.01440.x","volume":"14","author":"Y Shirota","year":"2008","unstructured":"Shirota Y, Illei GG, Nikolov NP (2008) Biologic treatments for systemic rheumatic diseases. Oral Dis 14(3):206\u2013216","journal-title":"Oral Dis"},{"issue":"1","key":"1238_CR85","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","volume":"53","author":"JA Smith","year":"2005","unstructured":"Smith JA, Thompson DJ, Whitcup SM et al (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53(1):18\u201323","journal-title":"Arthritis Rheum"},{"issue":"9602","key":"1238_CR86","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M et al (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370(9602):1861\u20131874","journal-title":"Lancet"},{"issue":"15","key":"1238_CR87","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med 337(15):1029\u20131035","journal-title":"N Engl J Med"},{"issue":"7","key":"1238_CR88","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/art.21121","volume":"52","author":"SM Tse","year":"2005","unstructured":"Tse SM, Burgos-Vargas R, Laxer RM (2005) Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 52(7):2103\u20132108","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1238_CR89","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P et al (2009) Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60(7):1884\u20131894","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1238_CR90","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","volume":"47","author":"P Tynj\u00e4l\u00e4","year":"2008","unstructured":"Tynj\u00e4l\u00e4 P, Kotaniemi K, Lindahl P et al (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47(3):339\u2013344","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1238_CR91","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","volume":"66","author":"P Tynj\u00e4l\u00e4","year":"2007","unstructured":"Tynj\u00e4l\u00e4 P, Lindahl P, Honkanen V et al (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66(4):548\u2013550","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1238_CR92","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MD.0b013e318190cfb7","volume":"87","author":"JC Hilst van der","year":"2008","unstructured":"van der Hilst JC, Bodar EJ, Barron KS et al (2008) International HIDS Study Group. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 87(6):301\u2013310","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1238_CR93","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.berh.2005.11.008","volume":"20","author":"CA Wallace","year":"2006","unstructured":"Wallace CA (2006) Current management of juvenile idiopathic arthritis. Best Practice Res Clin Rheumatol 20(2):279\u2013300","journal-title":"Best Practice Res Clin Rheumatol"},{"issue":"2","key":"1238_CR94","first-page":"259","volume":"20","author":"D Wendling","year":"1993","unstructured":"Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J Rheumatol 20(2):259\u2013262","journal-title":"J Rheumatol"},{"issue":"3","key":"1238_CR95","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/adc.88.3.186","volume":"88","author":"N Wilkinson","year":"2003","unstructured":"Wilkinson N, Jackson G, Gardner-Medwin J (2003) Biologics therapies for juvenile arthritis. Arch Dis Child 88(3):186\u2013191","journal-title":"Arch Dis Child"},{"issue":"9617","key":"1238_CR96","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M et al (2008) Efficacy and safety of tocilizumab in patients with systemic-onset idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998\u20131006","journal-title":"Lancet"},{"issue":"3","key":"1238_CR97","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/art.20944","volume":"52","author":"S Yokota","year":"2005","unstructured":"Yokota S, Miyamae T, Imagawa T et al (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52(3):818\u2013825","journal-title":"Arthritis Rheum"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-010-1238-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-010-1238-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-010-1238-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:22:06Z","timestamp":1559082126000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-010-1238-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,17]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["1238"],"URL":"https:\/\/doi.org\/10.1007\/s00431-010-1238-z","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,17]]}}}